0001209191-23-042101.txt : 20230712 0001209191-23-042101.hdr.sgml : 20230712 20230712170038 ACCESSION NUMBER: 0001209191-23-042101 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230710 FILED AS OF DATE: 20230712 DATE AS OF CHANGE: 20230712 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Broder Samuel CENTRAL INDEX KEY: 0001340543 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39980 FILM NUMBER: 231085205 MAIL ADDRESS: STREET 1: C/O SENSEI BIOTHERAPEUTICS, INC. STREET 2: 1405 RESEARCH DR., STE. 125 CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sensei Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001829802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1405 RESEARCH BLVD, SUITE 125 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: (240) 243-8000 MAIL ADDRESS: STREET 1: 1405 RESEARCH BLVD, SUITE 125 CITY: ROCKVILLE STATE: MD ZIP: 20850 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-07-10 0 0001829802 Sensei Biotherapeutics, Inc. SNSE 0001340543 Broder Samuel C/O SENSEI BIOTHERAPEUTICS, INC. 451 D STREET, SUITE 710 BOSTON MA 02210 1 0 0 0 0 Common Stock 2023-07-10 4 A 0 4466 0.00 A 8932 D Stock Option (Right to Buy) 1.22 2023-07-10 4 A 0 14550 0.00 A 2033-07-09 Common Stock 14550 14550 D These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer through such vesting date. The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date. /s/ Mark Ballantyne, Attorney-in-Fact 2023-07-12